The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib

Tao Shen(University of Oklahoma Health Sciences Center), Jie Wu(University of Oklahoma Health Sciences Center)
npj Precision Oncology
June 7, 2021
Cited by 49


Related Papers